Skip to Content

T. Rowe Price Health Sciences PRHSX

Analyst rating as of
NAV / 1-Day Return
86.61  /  1.79 %
Total Assets
15.7 Bil
Adj. Expense Ratio
0.750%
Expense Ratio
0.750%
Fee Level
Low
Longest Manager Tenure
6.24 years
Category
Health
Investment Style
Large Growth
Min. Initial Investment
2,500
Status
Open
TTM Yield
0.00%
Turnover
34%

Morningstar’s Analysis

Will PRHSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Offers an edge in the healthcare sector.

Senior Analyst

Summary

| |

T. Rowe Price Health Sciences has the expertise and structure it needs to add value in this rapidly evolving market segment, resulting in a Morningstar Analyst Rating of Silver.

Unlock our full analysis with Morningstar Investor